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Abstract
Background: Hepatocellular carcinoma (HCC) with biliary tumor thrombus (BTT) is rare and its impact on
postoperative prognosis remains controversial. The aim of this study was to evaluate the published evidence
concerning the outcome of surgical resection of HCC with BTT.
Methods: Eligible studies were identified by searching PubMed and reviewed systematically. Comparisons of
the clinicopathologic features and surgical outcomes for HCC patients with or without BTT were analyzed using
meta-analytical techniques.
Results: Twenty retrospective studies containing 598 patients that met the selection criteria were included for
review. The perioperative mortality was 2.1 % (range, 0–10 %), and the median 5-year overall survival (OS) was
24 % (range, 0–48 %) with a recurrence rate of 63.9 % (range, 42–91 %). Pooled analysis of 13 comparative studies
showed that HCC patients with BTT had a higher incidence of vascular invasion (odds ratio [OR]: 4.70, 95 % CI:
2.90–7.60; P <0.001), a higher frequency of poor differentiation (OR: 2.07, 95 % CI: 1.23–3.49; P = 0.006), and a shorter
5-year OS rate (OR: 0.31, 95 % CI: 0.21–0.64; P <0.001) than those without BTT.
Conclusions: Although HCC with BTT has more aggressive biological characteristics and is an indicator of poor
prognosis, surgical resection can still provide long-term survival for some patients.
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Background
Hepatocellular carcinoma (HCC) is the fifth most com-
mon neoplasm in the world and is the third leading
cause of cancer-related death worldwide, with more than
500 000 new cases diagnosed each year [1]. Surgical re-
section remains the mainstay of curative treatment for
this disease. Portal vein thrombus is a frequent event in
HCC and has important impact on patient survival after
surgical resection [2], while biliary tumor thrombus
(BTT) is relatively rare with a reported incidence of
0.53–12.9 % in autopsy and surgical specimens [3–9]. In
this regard, few reports are available in the literature
addressing the role of surgical resection for this special
clinical entity. In addition, the prognostic impact of BTT
is controversial [5, 6, 9]. The current study assesses the
published literature on surgical resection for HCC with
BTT and compares the clinicopathologic features and
long-term postoperative outcomes between HCC pa-
tients with BTT and those without BTT.
Methods
Systematic search strategy
A comprehensive systematic review of all published lit-
erature from 1966 to September 2015 was undertaken
using PubMed database. The following Medical Subject
Headings terms were used: “hepatocellular carcinoma,”
“biliary tumor thrombus,” “bile duct tumor thrombus,”
and “bile duct thrombus.” Reference lists of all retrieved
articles were manually searched to identify further po-
tentially relevant articles. This study was performed
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according to Preferred Reporting Items for Systematic
Reviews and Meta-analyses (PRISMA) guideline guide-
lines [10].
Inclusion and exclusion criteria
English language studies with a sample size of at least 10
patients that reported long-term survival data following
surgical resection for HCC with BTT were included. Ani-
mal studies, letters, reviews, abstracts, editorials, expert
opinions, duplicates, studies with fewer than 10 patients,
studies involving patients who were treated with nonsurgi-
cal management or liver transplantation were excluded.
Data extraction and quality assessment
Information on study design, first author, country or
region, year of publication, study population characteris-
tics, and outcomes of interest were independently ex-
tracted by two authors (Yanming Zhou and Feng Yu).
Discrepancies between the two reviewers were resolved
by discussion and consensus. Study methodology quality
was categorized according to the Evidence-based Medi-
cine Levels of Evidence [11].
Macroscopic BTT was defined when it was present in
the common hepatic duct or the first to second branches
of the bile duct and microscopic BTT was defined when
it was present in the third order or more peripheral
branches of the bile duct [12].
The primary outcome measures were 1-, 3- and 5-year
overall survival (OS) following surgical resection.
Statistical analysis
Data extracted for BTT group were reported as total and
percentage for categorical variables and as median values
and range for continuous variables, unless otherwise stated.
The results of comparative studies of patients with BTT
and without BTT were pooled by the use of Review Man-
ager.software, version 5.1 (The Cochrane Collaboration,
Software Update, Oxford). Dichotomous variables were
expressed as odds ratio (OR) with a 95 % confidence inter-
val (95 % CI), and continuous variables were expressed as
the weighted mean difference (WMD) with a 95 % CI. χ2
test and I2 were used to assess heterogeneity between stud-
ies. The random-effect model was used if there was signifi-
cant heterogeneity (P < 0.1); otherwise, the fixed-effect
model was used. Publication bias was evaluated via funnel
plot. Statistical significance was set at P < 0.05.
Results
Systematic review
Among 154 potentially relevant papers identified by the
initial search, 20 finally met the inclusion criteria in this
review and are summarised in Table 1 [3–9, 12–26]. All
studies were retrospectively designed, originated from
Asia (Japan, n = 8 [5, 6, 12, 13, 15, 20, 21, 25]; Mainland
China, n = 7 [7, 8, 14, 16, 17, 19, 26]; Korea, n = 2
[18, 22]; Taiwan, n = 1 [9]; India, n = 1 [23]; Hong
Kong, n = 1 [24]) and classified as level-4 evidence. The
sample size of each study varied from 13 to 73 patients.
Thirteen studies utilised patients without BTT as a control
group for comparison [5, 6, 9, 13, 15–17, 19–24].
The included papers described 598 patients who
underwent surgical resection for HCC with BTT, includ-
ing 526 (88 %) patients who had macroscopic BTT and
72 (12 %) patients who had microscopic BTT. Most
(80.2 %, 441/550) patients were men. The median or
mean age ranged from 47.1 to 60 (median = 54.2) years.
Hepatitis B surface antigen (HBsAg) and hepatitis C virus
antibody (Anti-HCV) were positive in 60.7 % (324/533)
and 14.9 % (50/335) of patients, respectively. Mean or me-
dian tumor size ranged from 3.8 to 6.4 (median = 5.4) cm.
Cirrhosis, tumor multiplicity, vascular invasion, poor dif-
ferentiation, intrahepatic metastasis, and tumor capsule
absence, occurred in 60.4 % (229/379), 36.8 % (127/345),
67.1 % (306/456), 47.9 % (188/392), 31.6 % (92/291), and
66.7 % (140/210) of patients, respectively.
Table 2 shows the operative intervention and postopera-
tive outcomes. Among 573 patients with available informa-
tion, hepatectomy with or without tumor thrombectomy
was carried out in 423 (73.8 %), followed by hepatectomy
combined bile duct resection in 144 (25.1 %), thrombec-
tomy only in 4 (0.7 %), and thrombectomy with hepatic ar-
tery ligation and cannulation in 2 (0.35 %). There were 13
perioperative deaths (2.1 %) (range, 0–10 %). The median
overall survival was 26.1 months (range, 11.4–47 months).
The median 1-, 3- and 5-year OS rates were 72 % (range,
38–93 %), 39 % (range, 11–77 %) and 24 % (range, 0–48 %),
respectively. Disease recurrence developed in 64.8 % (310/
478) patients.
Meta-analysis
A total of 13 comparative studies including 334 patients
with BTT and 6361 without BTT were included for ana-
lysis [5, 6, 9, 13, 15–17, 19–24]. Table 3 presents a sum-
mary of outcomes. Table 3 presents a summary of the
outcomes. There was no significant difference in clinico-
pathological characteristics between the two groups in
terms of sex, age, hepatitis viral status (hepatitis B or C
virus), presence of cirrhosis, tumor size and multiplicity,
tumor capsule absence, and intrahepatic metastasis,
while vascular invasion (OR: 4.70, 95 % CI: 2.90–7.60;
P <0.001) and poor differentiation (OR: 2.07, 95 % CI:
1.23–3.49; P = 0.006) were more frequently observed
in BTT group than those in non-BTT group.
The 1-, 3- and 5-year OS rates in patients with BTT
were significantly lower than those in patients without
BTT (OR: 0.48, 95 % CI: 0.31–0.73; P <0.001; OR: 0.45,
95 % CI: 0.29–0.680; P <0.001; OR: 0.31, 95 % CI: 0.21 –
0.64; P < 0.001, respectively) (Figs. 1, 2 and 3).
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Table 1 Clinical background of included studies
First author (Year) No. M/F Age (years) a BTT type Ma/Mi HBsAg n (%) Anti-HCV n (%) Cirrhosis n (%) TS (cm) a MT n (%) VI n (%) PD n (%) IM n (%) TCA n (%)
Satoh (2000) [5] 17 15/2 58.2 17/0 5 (29.4) – – – – 11 (64.8) 5 (29.4) – –
Shiomi (2001) [6] 17 15/2 58.8 17/0 7 (46.7) 3 (17.6) 6 (35 %) 6.1 12/16 (75) 13 (76) 0 (0) 5 (29) –
Peng (2004) [7] 15 b 10/5 49 15/0 13 (86.7) – – 5.1 2 (13.3) 5 (33.3) – – –
Qin (2004) [8] 34 28/6 48.5 34/0 34 (100) – 32 (94.1) 6.4 – – – – 34 (100)
Yeh (2004) [9] 17 14/3 52.3 17/0 – – – 3.8 – 12/16 (75) 3/11 (27.2) 5/16 (83.3) 2/11 (18.2)
Esaki (2005) [12] 38 32/6 62 19/19 8 (21.1) – 10 (26.3) 6.2 19 (50) 27 (71) 11 (28.9) 19 (50) –
Ikenaga (2009) [13] 15 12/3 66 10/5 4 (27.7) 7 (46.7) – 5.0 6 (40) 12/14 (85.7) – 10 (66.7) 2 (13.3)
Luo (2009) [14] 48 c – – 48/0 – – – 6.2 – – – – –
Noda (2011) [15] 22 21/1 58 22/0 15 (68.1) 5 (22.7) 6 (27.2) >5, n = 9 20 (90.9) 13 (59) 18 (81.8) – –
Shao (2011) [16] 27 24/3 47.1 24/3 26 (96.7) 0 (0) 18 (66.7) >5, n = 10 – 17 (62.9) 26 (96.3) 5 (18.5) 21 (77.7)
Yu (2011) [17] 20d 17/3 50.6 20/0 16 (80) – 14 (70) 4.5 – 12 (60) 13 (65) 4 (20) 15 (75)
Moon (2013) [18] 73 52/21 54.2 73/0 59 (80.8) 2 (2.8) 62 (84.9) 5.8 11 (15) 53 (72.6) 54 (74) 25 (34.2) –
Meng (2014) [19] 35 24/11 51.3 28/7 26 (74.3) 0 (0) 25 (65.8) >5, n = 24 15 (42.8) 10 (25.8) 10 (25.8) – 24 (68.6)
Oba (2014) [20] 13 12/1 61 13/0 4 (30.7) 5 (38.5) 3 (23) 4.4 2 (15.4) 12 (92.3) – – –
Kasai (2015) [21] 44 35/9 64 44/0 8 (18.2) 21 (52.5) 14 (31.8) 5.8 16 (36.4) 31 (70.4) 18 (40.9) – –
Kim (2015) [22] 31 21/10 53 0/31 26 (83.9) 1 (3.2) – 4.8 – 28 (90.3) 1 (3.2) 8 (25.8) 7 (22.5)
Rammohan (2015) [23] 39 28/11 52.1 39/0 7 (17.9) 2 (5.1) Excluded 5.6 – – – – –
Wong (2015) [24] 37 29/8 57 37/0 30 (81.1) – – 6 15 (29.7) 25 (67.6) 11 (29.7) – 35 (94.6)
Yamamoto (2015) [25] 19 19/0 67 19/0 7 (36.8) 4 (21) 6 (31.5) 4.3 – – – – –
Zeng (2015) [26] 37 33/4 50 30/7 29 (78.4) – 33 (89.2) 4.9 9 (24.3) 25 (67.5) 23 (62.2) 6 (16.2) –
M male, F female, Ma macroscopic, Mi microscopic, HBsAg hepatitis B surface antigen, anti-HCV hepatitis C virus antibody, ST solitary tumor, TS tumor size, MT multiple tumor, VI vascular invasion, PD poor
differentiation, IM intrahepatic metastasis, TCA tumor capsule absence
a mean or median













Table 2 Operative intervention and outcomes





5 12 (70.6) 5 (29.4) 0 (0) 0 (0) – 58 30 16 10/15 (66.7)
6 12 (70.6) 5 (29.4) 0 (0) 0 (0) 17.6 75 47 28 11 (64.7)
7 7 (50) 4 (28.5) 3 (21.4) 1 (7.1) 14 73 51 21 7 (100)
8 30 (88.2) 1 (2.9) 1 (2.9) 1 (2.9) – 71 11 – 14/28 (50)
9 – – – 1 (5.9) 20.8 60 20 6.7 11/16 (68.7)
12 33 (86.8) 5 (13.2) 0 (0) 0 (0) 31 79 45 33 29 (76.3)
13 12 (80) 3 (20) 0 (0) 0 (0) 11.4 46 23 0 11 (73.3)
14 40 (93) 3 (7) 0 (0) 1 (2.1) 37 93 56 24 10 (21)
15 20 (90.9) 2 (9.1) 0 (0) 0 (0) – 62 30 30 13/16 (81.2)
16 26 (96.3) 1 (3.7) 0 (0) 1 (3.7) – 70 26 7.4 25/26 (96.1)
17 12 (66.7) 6 (33.3) 0 (0) 2 (10) – 73 21 – 7/13 (53.8)
18 42 (57.5) 31 (42.5) 0 (0) 3 (4.1) – 77 41 32 52/70 (74.3)
19 25 (71.4) 10 (28.6) 0 (0) 0 (0) 19 38 20 11 –
20 7 (53.8) 6 (46.2) 0 (0) 0 (0) 47 92 77 48 6 (46.1)
21 37 (84) 7 (16) 0 (0) 2 (4.5) 23.7 70 38 31 30/41 (73.2)
22 31 (100) 0 (0) 0 (0) 0 (0) – 90 61 – 20 (64.5)
23 30 (76.9) 9 (23.1) 0 (0) 2 (5.1) 28.6 82 48 10 –
24 9 (24.3) 28 (75.7) 0 (0) 0 (0) 44 69 54 39 23 (62.1)
25 15 (78.9) 4 (21.1) 0 (0) 0 (0) – 82 39 32 10/15 (66.7)
26 23 (62.2) 14 (37.8) 0 (0) 0 (0) – 64 24 18 21 (56.8)
Hx hepatectomy, Tb thrombectomy, BDR bile duct resection
Table 3 Results of meta-analysis comparing hepatocellular carcinoma with or without biliary tumor thrombus
Outcome of interest No. of studies No. of patients BTT Non-BTT OR/WMD 95 % CI P value HG P value
Clinicopathological characteristics
Male 12 317 5806 1.07 0.97, 1.43 0.67 0.69
Age 9 256 3840 0.01 −1.01, 1.02 0.99 0.01
Hepatitis B surface antigen 11 297 5150 1.33 0.99, 1.79 0.06 0.35
Hepatitis C virus antibody 9 243 4274 0.72 0.37, 1.39 0.33 0.03
Cirrhosis 6 158 3569 0.72 0.51, 1.00 0.05 0.11
Tumor size 7 177 4028 −0.89 −2.63, 0.85 0.32 <0.001
Multiple tumor 6 166 3662 1.85 0.76, 4.52 0.18 <0.001
Tumor capsule absence 7 176 2305 1.26 0.63, 2.51 0.62 0.02
Intrahepatic metastases 5 109 1710 1.47 0.93, 2.33 0.10 0.40
Vscular invasion 12 293 5939 4.70 2.90, 7.60 <0.001 0.001
Poor differentiation 8 227 4003 2.07 1.23, 3.49 0.006 0.05
Long-term outcomes
1-year overall survival 12 280 4739 0.48 0.31, 0.72 <0.001 0.02
3-year overall survival 12 280 4739 0.45 0.29, 0.68 <0.001 0.007
5-year overall survival 10 231 4021 0.31 0.21, 0.64 <0.001 0.02
BTT biliary tumor thrombus, OR odds ratio, WMD weighted mean difference, CI confidence interval, HG heterogeneity
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A funnel plot analyzing all studies utilized in the 1-
year OS analysis demonstrated asymmetry, suggesting
the presence of publication bias (Fig. 4).
Discussion
HCC patients with BTT usually respond poorly to non-
surgical treatments, such as transcatheter arterial che-
moembolization (TACE), percutaneous transhepatic
biliary drainage, and radiation. Oba et al. [20] reported
that the 1-, 3-, and 5-year OS rate in their 25 patients
was 14 %, 5 % and 0 % after nonsurgical treatment, re-
spectively. Luo et al. [14] reported a 5-year OS rate of
0 % for patients treated with TACE (n = 27) or biliary de-
compression (n = 40). In this study, patients who re-
ceived surgical resection had a 5-year OS rate of 24 %,
which is far better than the results of the nonsurgical
treatments discussed above. So it seems justified to carry
out surgical resection for this group of patients.
We found that long-term survival in patients with
BTT was significantly shorter than that in patients with-
out BTT. This may be a consequence of the fact that
BTT has more aggressive biologically characteristics. As
showed in the current study, the incidence of vascular
invasion and poor differentiation, two powerful unfavor-
able prognostic factors, were more frequently observed
in BTT group than those in non-BTT group.
The high incidence of postoperative recurrence limits
the potential for surgical cure of HCC. Postoperative re-
currence is usually classified as early (≤1 year) and late
(>1 year) recurrence. Early recurrence was found to be
associated with worse prognosis compared with late re-
currence.27 Ikenaga et al. [13] reported that 53 % of their
patients in BTT group developed recurrences in the
remnant liver within 3 months after surgery. Qin [8],
Noda [15], Shao [16], Zeng [26] and their colleagues re-
ported that more than 50 % of their BTT patients expe-
rienced recurrences during the first year after surgery.
Shao et al. [16] found that patients with BTT had a
higher rate of early recurrence than those without BTT
(70.3 % vs. 34.8 %; P < 0.001). In aggregate, these results
suggest that patients with BTT had a higher propensity
for early recurrence. It is widely accepted that early re-
currence is mainly caused by intrahepatic metastasis
from the primary tumor via the venous circulation [27].
Fig. 1 Result of the meta-analysis on 1-year overall survival
Fig. 2 Result of the meta-analysis on 3-year overall survival
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As most patients with BTT also had vascular invasion, it
is understandable that BTT is likely to recur early after
resection. On the other hand, Ikenaga et al. [13] re-
ported two cases of BTT patients without vascular inva-
sion who developed early recurrence in the remnant
liver. Similarly, Shao et al. [16] reported nine cases of
BTT patients without vascular invasion who experienced
early recurrence. These data indicate that dissemination
via the bile duct system is another gate of intrahepatic
metastasis. In the American Joint Committee on Cancer
(AJCC)/International Union Against Cancer (UICC) sta-
ging system, information of BTT is not required [28]. In
contrast, in the Liver Cancer Study Group of Japan
(LCSGJ) staging system, patients with BTT are assigned
to the advanced stage and had a less favorable prognosis
[29]. Based on the results of the present study, the
LCSGJ staging system appears to be more appropriate
for HCC lesions than the AJCC/UICC system.
The necessity of bile duct resection for HCC with
macroscopic BTT is a subject of debate. Some authors
found that BTT rarely invaded the bile duct wall around
the hepatic hilus and could be easily removed [5, 6, 15, 25].
Besides, analysis of the OS rate by some studies showed
that bile duct resection did not seem to provide any signifi-
cant benefit [5, 6, 15], and therefore they suggested that
such resection should be avoided unless essential for tech-
nical purposes. Whereas other authors advocated routine
bile duct resection for HCC patients with BTT, knowing
that it may minimize recurrence due to better eradication
of the microscopic tumor [24, 26]. As all these studies in-
volved the analysis of only a small number of patients,
comparisons of the results between the two groups may be
of limited value, and therefore future studies with a larger
number of patients are required.
There have been relatively few studies in the literature
reporting the practice and outcome of liver transplant-
ation for the treatment of HCC with BTT. Peng et al. [7]
reported one patient who died of recurrence at 27 months
after liver transplantation. Hwang et al. [30] reported a 5-
year OS rate of 50 % in a cohort of 14 patients. Although
these authors believed that liver transplantation may be a
potential treatment option for HCC with BTT, it is pru-
dent to draw any firm conclusion before more results are
obtained from further studies with larger sample sizes.
The present study has several limitations. First, all the
included studies were performed in the Asia-Pacific re-
gion, which may affect the generalizability. In addition,
the retrospective nature of eligible studies is vulnerable
to introduce potential bias. For example, there were dif-
ferences in observation periods, disease stages and surgi-
cal methods between the institutions. For this reason,
significant heterogeneity was tested in the meta-analytic
statistical outcomes. Finally, as only 13 of the 20 in-
cluded studies were eligible for meta-analysis, the impact
of BTT on the prognosis may be underestimated.
Conclusions
HCC with BTT has aggressive biological characteristics and
is an indicator of poor prognosis. However, surgical resec-
tion can still provide long-term survival for some patients.
More effective adjuvant therapies need to be developed to
improve the outcome. Adoptive immunotherapy [31],
Fig. 3 Result of the meta-analysis on 5-year overall survival
Fig. 4 Funnel plot analysis of publication bias. The outcome was the
1-year overall survival
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antiviral therapy [32, 33], intrahepatic injection of 131I-
lipiodol [34], and sorafenib- or peretinoin-based chemo-
therapy [35, 36] may provide beneficial effects.
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